Module-based multiscale simulation of angiogenesis in skeletal muscle.

Systems Biology Laboratory, Department of Biomedical Engineering, School of Medicine, Johns Hopkins University, Baltimore, MD 21205, USA.
Theoretical Biology and Medical Modelling (Impact Factor: 1.27). 04/2011; 8:6. DOI: 10.1186/1742-4682-8-6
Source: PubMed

ABSTRACT Mathematical modeling of angiogenesis has been gaining momentum as a means to shed new light on the biological complexity underlying blood vessel growth. A variety of computational models have been developed, each focusing on different aspects of the angiogenesis process and occurring at different biological scales, ranging from the molecular to the tissue levels. Integration of models at different scales is a challenging and currently unsolved problem.
We present an object-oriented module-based computational integration strategy to build a multiscale model of angiogenesis that links currently available models. As an example case, we use this approach to integrate modules representing microvascular blood flow, oxygen transport, vascular endothelial growth factor transport and endothelial cell behavior (sensing, migration and proliferation). Modeling methodologies in these modules include algebraic equations, partial differential equations and agent-based models with complex logical rules. We apply this integrated model to simulate exercise-induced angiogenesis in skeletal muscle. The simulation results compare capillary growth patterns between different exercise conditions for a single bout of exercise. Results demonstrate how the computational infrastructure can effectively integrate multiple modules by coordinating their connectivity and data exchange. Model parameterization offers simulation flexibility and a platform for performing sensitivity analysis.
This systems biology strategy can be applied to larger scale integration of computational models of angiogenesis in skeletal muscle, or other complex processes in other tissues under physiological and pathological conditions.

  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Background Currently, most biomedical models exist in isolation. It is often difficult to reuse or integrate models or their components, in part because they are not modular. Modular components allow the modeler to think more deeply about the role of the model and to more completely address a modeling project¿s requirements. In particular, modularity facilitates component reuse and model integration for models with different use cases, including the ability to exchange modules during or between simulations. The heterogeneous nature of biology and vast range of wet-lab experimental platforms call for modular models designed to satisfy a variety of use cases. We argue that software analogs of biological mechanisms are reasonable candidates for modularization. Biomimetic software mechanisms comprised of physiomimetic mechanism modules offer benefits that are unique or especially important to multi-scale, biomedical modeling and simulation.ResultsWe present a general, scientific method of modularizing mechanisms into reusable software components that we call physiomimetic mechanism modules (PMMs). PMMs utilize parametric containers that partition and expose state information into physiologically meaningful groupings. To demonstrate, we modularize four pharmacodynamic response mechanisms adapted from an in silico liver (ISL). We verified the modularization process by showing that drug clearance results from in silico experiments are identical before and after modularization. The modularized ISL achieves validation targets drawn from propranolol outflow profile data. In addition, an in silico hepatocyte culture (ISHC) is created. The ISHC uses the same PMMs and required no refactoring. The ISHC achieves validation targets drawn from propranolol intrinsic clearance data exhibiting considerable between-lab variability. The data used as validation targets for PMMs originate from both in vitro to in vivo experiments exhibiting large fold differences in time scale.Conclusions This report demonstrates the feasibility of PMMs and their usefulness across multiple model use cases. The pharmacodynamic response module developed here is robust to changes in model context and flexible in its ability to achieve validation targets in the face of considerable experimental uncertainty. Adopting the modularization methods presented here is expected to facilitate model reuse and integration, thereby accelerating the pace of biomedical research.
    BMC Systems Biology 08/2014; 8(1):95. · 2.85 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: A timely restoration of the ruptured blood vessel network in order to deliver oxygen and nutrients to the fracture zone is crucial for successful bone healing. Indeed, oxygen plays a key role in the aerobic metabolism of cells, in the activity of a myriad of enzymes as well as in the regulation of several (angiogenic) genes. In this paper, a previously developed model of bone fracture healing is further improved with a detailed description of the influence of oxygen on various cellular processes that occur during bone fracture healing. Oxygen ranges of the cell-specific oxygen-dependent processes were established based on the state-of-the art experimental knowledge through a rigorous literature study. The newly developed oxygen model is compared with previously published experimental and in silico results. An extensive sensitivity analysis was also performed on the newly introduced oxygen thresholds, indicating the robustness of the oxygen model. Finally, the oxygen model was applied to the challenging clinical case of a critical sized defect (3 mm) where it predicted the formation of a fracture non-union. Further model analyses showed that the harsh hypoxic conditions in the central region of the callus resulted in cell death and disrupted bone healing thereby indicating the importance of a timely vascularization for the successful healing of a large bone defect. In conclusion, this work demonstrates that the oxygen model is a powerful tool to further unravel the complex spatiotemporal interplay of oxygen delivery, diffusion and consumption with the several healing steps, each occurring at distinct, optimal oxygen tensions during the bone repair process.
    Journal of Theoretical Biology 10/2014; · 2.35 Impact Factor
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Tumor growth is dependent on angiogenesis, a process whereby new capillaries are formed from pre-existing microvasculature. Inhibition of tumor-induced angiogenesis has proven to be an effective therapeutic strategy for several drugs currently in the clinic (1). One of the key molecules involved in tumor angiogenesis is vascular endothelial growth factor A (VEGF-A, commonly referred to as VEGF). Thus, an understanding of how VEGF is expressed, diffuses, and interacts with other important regulators such as VEGF receptors at molecular, cellular and tissue levels is critical to the evaluation of therapeutic effects (4). Computational modeling of these angiogenic events at multiple scales of biological organization provides a means to explore the regulatory mechanisms underlying the complex process. We have developed a number of computational models to investigate how VEGF transport events are linked with receptor signaling at the molecular scale, with cellular behavior and cell phenotypes at the cellular scale, and how these events combine to regulate angiogenesis at tissue and whole body levels (5, 6, 9). First, we apply an in vivo hemorheological model to simulate the distribution of blood flow and hematocrit in all the microvessels. We then use this distribution in a 3D convection-diffusion model to describe how oxygen is delivered by microvascular blood flow and its diffusion and utilization through the tissue. The oxygen transport model is important, as VEGF secretion by muscle and tumor cells is mediated by insufficient oxygen supply to the cell, in turn resulting in hypoxia or low partial pressure of oxygen (PO2); low PO2 is sensed by a transcription factor hypoxia-inducible factor HIF1alpha that activates hundreds of genes including VEGF (8). Next, we developed a reaction-diffusion model to predict molecular distribution of VEGF in the interstitial space and on the surface of endothelial and parenchymal cells (e.g. myocytes and tumor cells). The model describes the secretion of two major VEGF isoforms, VEGF121 and VEGF165, molecular transport of each isoform in the interstitial space, VEGF binding to heparan sulfate proteoglycans in the extracellular matrix (ECM), VEGF binding to receptors VEGFR1, VEGFR2 and co-receptors neuropilin-1 (NRP1) and neuropilin-2 (NRP2) on the surface of endothelial cells, myocytes, and tumor cells, and internalization of the ligand-receptor complexes. Next, a cellular agent-based model was developed to describe how capillary 6-3 Interdisciplinary Transport Phenomena VII, Dresden, Germany, 2011 Paper No.: ITP-2011-49 endothelial cells respond to stimuli, specifically VEGF concentration and gradients, during the time course of capillary sprout formation (7). The model applies logical rules, based on extensive experimental data, to define cell activation, elongation, migration and proliferation events, which in turn dynamically affect VEGF transport and gradients. In addition, a module-based istrategy was developed to integrate the computer models of the major steps of angiogenesis from the molecular to tissue levels, starting from blood flow, to oxygen transport, to HIF1alpha expression, to VEGF secretion and transport, to capillary growth (3). In order to understand the effect of VEGF concentration in the multiple tissues in the body and be able to simulate systemic administration of anti-VEGF therapeutic agents, we developed a whole-body compartmental model of VEGF transport (10, 12-14). The model is comprised of three compartments: normal tissue represented by skeletal muscle, the vascular or blood compartment, and tumor compartment; tissue interstitial space compartments are further subdivided into ECM, and endothelial and parenchymal basement membranes. The model includes the molecular interactions of VEGF121 and VEGF165, receptors VEGFR1, VEGFR2, and co-receptors NRP1 and NRP2. The density of VEGF receptors and co-receptors is determined experimentally using quantitative flow cytometry (2). We then add an anti-VEGF compound to the model, specifically bevacizumab, an anti-VEGF antibody used clinically for different types of cancer (11). Intercompartment transport of VEGF, anti-VEGF and their products includes vascular permeability and lymph flow. These molecules intravasate and extravasate via transendothelial macromolecular permeability, and can be convected from the normal tissue into the blood via lymphatic drainage, and they are removed from the blood via clearance. The compartmental model predicts the spatially-averaged interstitial concentration of VEGF and anti-VEGF, as well as ligand-receptor binding in different compartments. The model is used to investigate the effect of various therapies that target VEGF-mediated angiogenesis.

Full-text (3 Sources)

Available from
May 31, 2014